 EMERYVILLE, Calif., May 12, 2021 GLOBE NEWSWIRE -- 4D Molecular Therapeutics Nasdaq: FDMT, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced new preclinical data from non-human primate NHP studies of 4D-150, a dual transgene, intravitreal gene therapy inhibiting four distinct VEGF family members for the treatment of wet age-related macular degeneration wet AMD and diabetic macular edema DME. 